Carbidopa and Entacapone
Therapeutic interventions and adjustments in the management of Parkinson disease: role of combined carbidopa/levodopa/entacapone (Stalevo<sup>®</sup>)
8
Carbidopa/levodopa/entacapone: the evidence for its place in the treatment of Parkinson’s disease
10
Compatibility and stability studies of levadopa, carbidopa, entacapone and natural bioenhancer mixture
8
A VALIDATED RP HPLC METHOD FOR THE SIMULTANEOUS DETERMINATION OF LEVODOPA, CARBIDOPA AND ENTACAPONE IN TABLET DOSAGE FORMS
16
Levodopa/carbidopa and entacapone in the treatment of Parkinson’s disease: efficacy, safety and patient preference
10
Optimizing levodopa therapy for Parkinson’s disease with levodopa/carbidopa/entacapone: implications from a clinical and patient perspective
10
Levodopa/carbidopa/entacapone versus levodopa/dopa-decarboxyiase inhibitor for the treatment of Parkinson's disease: systematic review, meta-analysis, and economic evaluation
11
HPLC METHOD FOR ESTIMATION OF DRUG RELEASE OF ENTACAPONE IN ENTACAPONE, LEVODOPA AND CARBIDOPA TABLETS
10
HPLC METHOD FOR SIMULTANEOUS ESTIMATION OF DRUG RELEASE OF LEVODOPA AND CARBIDOPA IN ENTACAPONE, LEVODOPA AND CARBIDOPA TABLETS
11
STABILITY INDICATING METHOD OF CARBIDOPA AND LEVODOPA ASSAY IN CARBIDOPA, LEVODOPA AND ENTACAPONE FILM COATED TABLETS BY RP HPLC
9
Increased dose of carbidopa with levodopa and entacapone improves “off” time in a randomized trial
11
Voltammetric Determination of Carbidopa Using a modified Multiwall Carbon Nanotube Paste Electrode
10
Analytical Method Development and Validation of Entacapone Drug by Modern LC MS/MS Method to Quantify the Genotoxic Impurity
8
Simultaneous estimation of levodopa and carbidopa in bulk, pharmaceutical dosage forms and dissolution sample analysis by RP HPLC PDA method
7
DETERMINATION OF ENTACAPONE IN PHARMACEUTICAL FORMULATIONS BY RP-HPLC METHOD
7
Piggyback drug development: (Molecular docking of Entacapone analogues as direct M tuberculosis InhA inhibitors)
7
Dissolution Rate Enhancement of Entacapone and Formulation of its Oro- Dispersible Tablets: Applying Statistical Design
14
Levodopa/Carbidopa Intestinal Gel for Treatment of Advanced Parkinson’s Disease: An Update on the Effects of Cognitive Functions
12
Design and evaluation of entacapone controlled release trilayer matrix tablets in the management of parkinson’s disease
11
Surface adsorbed templates for directing the crystal growth of entacapone as monitored using process analytical techniques
30